For the quarter ended October 2024, Medtronic (MDT) reported revenue of $8.4 billion, up 5.3% over the same period last year. EPS came in at $1.26, compared to $1.25 in the year-ago quarter.The reported revenue represents a surprise of +1.75% over the Zacks Consensus Estimate of $8.26 billion. With the consensus EPS estimate being $1.24, the EPS surprise was +1.61%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectat ...

Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.61%. A quarter ago, it was expected that this medical device company would post earnings of $1.20 per share when it actually produced earnings of $1.23, delivering a surprise of 2.50%.Over the last four quarters, the co ...

Exhibit 99.1 Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 NEWS RELEASE Contacts: FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2025 financial results Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland – Nov. 19, 2024 – Medtronic plc (NYSE: MDT) today announced finan ...

Delivering on commitments, executing ahead of expectations, and raising guidanceInnovation driving sustained growth across many franchises:  TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and NeuromodulationGALWAY, Ireland, Nov. 19, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024.Key Highlights Revenue of $8.4 billion increased 5.3% as reported and 5.0% organic GAAP diluted earnings per ...

Analysts on Wall Street project that Medtronic (MDT) will announce quarterly earnings of $1.24 per share in its forthcoming report, representing a decline of 0.8% year over year. Revenues are projected to reach $8.26 billion, increasing 3.5% from the same quarter last year. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. A ...

Dr. Shirin Towfigh thought she had designed a medical device that would revolutionize hernia care for women. Now, Towfigh is suing Medtronic, a global leader in medical devices, accusing the company of stealing her patented design. A Beverly Hills surgeon with over 22 years of experience, Towfigh says she discovered that a significant number of her hernia patients experiencing post-surgery complications were women — and that most mesh designs on the market were primarily tailored to the male anatomy.In 2016 ...

HONG KONG and SHANGHAI, Nov. 7, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) established a strategic partnership with Medtronic (Shanghai) Management Co., Ltd. ("Medtronic") at the 7th China International Import Expo (CIIE) held at the National Exhibition and Convention Center (Shanghai) on 6 November, 2024. Leveraging their respective strengths, the two companies will collaborate extensively on cardia ...

Medtronic plc (MDT) is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell. In the last reported quarter, the company's adjusted earnings of $1.23 exceeded the Zacks Consensus Estimate by 2.5%. Medtronic beat estimates in each of the trailing four quarters, the average surprise being 3.07%. The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $8.26 billion, suggesting growth of 3.5% year over year. The consensus estimate for second-quarter earni ...

GALWAY, Ireland, Nov. 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's second quarter of fiscal year 2025, which ended on Fri ...

Healthcare Industry Overview - Defensive industries like healthcare are attractive to income investors due to their resilience during economic downturns, as medical needs are non-optional [2] - The healthcare sector is home to many excellent dividend stocks, including Merck and Medtronic [2] Merck (MRK) - Merck's shares are down by 4% this year, partly due to investor concerns about potential competition for its key cancer drug, Keytruda [3] - Keytruda, Merck's largest growth driver, faces competition from Summit Therapeutics' ivonescimab in non-small cell lung cancer (NSCLC) [3] - Keytruda will lose patent exclusivity in the U.S. in 2028, but its revenue is expected to grow until then due to FDA approvals across multiple indications [4] - Merck is developing a subcutaneous version of Keytruda, which will retain exclusivity post-2028 [4] - The company has a robust pipeline with several dozen programs and has expanded through acquisitions, such as Acceleron Pharma, leading to the approval of Winrevair for pulmonary arterial hypertension [5] - Merck collaborates with smaller companies, including Moderna, on a personalized cancer vaccine [6] - Merck's dividend payouts have increased by 71% over the past decade, with a forward yield of 2.96%, higher than the S&P 500 average of 1.32% [6] - Merck remains a reliable income stock with a strong dividend record [7] Medtronic (MDT) - Medtronic has increased its dividend payouts for 47 consecutive years, showcasing its strong business model [8] - The company operates in over 100 countries and offers a wide range of medical devices across several categories [8] - Medtronic's diabetes care segment, particularly its MiniMed 780G insulin pump with meal-detection technology, is a significant growth driver [9] - The company is developing the Hugo robotic-assisted surgery system, which could benefit from the growing demand for minimally invasive surgeries due to the aging population [9][10] - Medtronic has faced challenges in revenue growth recently but is expected to recover and continue increasing its dividend payouts in the long term [11]